Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) in a report released on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company's stock.
Several other analysts have also commented on the stock. Guggenheim increased their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. HC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.75.
View Our Latest Research Report on ANI Pharmaceuticals
ANI Pharmaceuticals Stock Performance
NASDAQ ANIP traded up $1.86 on Friday, hitting $64.35. The stock had a trading volume of 334,305 shares, compared to its average volume of 238,112. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -117.00 and a beta of 0.63. The company's 50-day moving average is $58.59 and its two-hundred day moving average is $58.07.
Insiders Place Their Bets
In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,700 shares of company stock worth $610,201 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On ANI Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE increased its position in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV grew its holdings in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after purchasing an additional 579 shares during the period. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $166,000. Finally, HighTower Advisors LLC bought a new position in ANI Pharmaceuticals in the third quarter valued at approximately $222,000. 76.05% of the stock is owned by institutional investors.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Stories
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
